Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

IN BRIEF: WuXi Biologics signs exclusive deal with GSK

5th Jan 2023 09:05

WuXi Biologics Inc - China-based contract research, development & manufacturing organisation, offering end-to-end biologics solutions - Enters into a license deal with GSK PLC for one preclinical bi-specific T cell engaging antibody and the option of three additional bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms. Says WuXi Biologics will get an upfront payment of USD40 million and tiered royalties on net sales.

WuXi Biologics Chief Executive Officer Chris Chen says: "We are looking forward to enabling GSK to bring these potentially life-saving therapeutics to more patients worldwide."

WuXi Biologics current stock price: HKD67.50

12-month change: down 14%

GSK current stock price: 1,427.60 pence, down 1.4% on Thursday morning in London

12-month change: down 12%

By Xindi Wei, Alliance News reporter

Comments and questions to [email protected]

Copyright 2023 Alliance News Ltd. All Rights Reserved.

FTSE 100 Latest